List of works - James Larkin

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review ⬇️

scientific article published on April 19, 2012

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

scientific article published on 10 September 2017

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

scientific article published on 15 April 2018

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

scientific article published on 14 October 2020

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

scientific article published on 01 December 2018

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

scientific article published on 18 September 2020

Adjuvant nodal irradiation in melanoma

scientific article published on 01 August 2012

Advances in immunotherapy for melanoma

scientific article published on 01 August 2014

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

scientific article published on 20 December 2018

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 02 January 2020

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

scientific article published on 20 November 2017

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

scientific article published on 29 July 2020

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies ⬇️

scientific article published on February 1, 2011

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

scientific article

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

scientific article published on 29 July 2016

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article (publication date: 2 July 2015)

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

scientific article

Corrigendum re “Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma” [Eur Urol 2017;72:747–54]

scholarly article published in European Urology

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

scientific article published on 13 March 2018

Current and future systemic treatments for renal cell carcinoma ⬇️

scientific article published on June 13, 2012

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? ⬇️

scientific article published on October 1, 2010

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib

scientific article published on 04 June 2019

Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma

scientific article published on July 1, 2012

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

scientific article published on 7 December 2017

Endobronchial metastases from renal cell carcinoma: A late manifestation of the disease with an increasing incidence ⬇️

scientific article published on 03 September 2012

Expanded access programmes: patient interests versus clinical trial integrity

scientific article published on 29 December 2014

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

scientific article published on 28 September 2019

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

scientific article published on 3 June 2013

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

scientific article

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

scientific article

Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma ⬇️

scientific article published on 7 August 2017

Genome-wide association study identifies multiple risk loci for renal cell carcinoma ⬇️

scientific article

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma

scientific article published on 01 March 2019

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

scientific article published on 13 February 2018

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

scientific article published on 16 August 2019

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

scientific article published on 03 August 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

scientific article

Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?

scientific article published on 22 September 2015

Ipilimumab activity in advanced uveal melanoma ⬇️

scientific article published on February 1, 2013

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

scientific article published on 18 September 2020

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

scientific article published on 27 January 2021

Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Sunitinib ⬇️

scientific article published on August 2, 2010

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

New targeted therapies for renal cell carcinoma ⬇️

scientific article published on April 21, 2011

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

scientific article

Non–Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities ⬇️

scientific article published on June 1, 2011

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

scientific article

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

scientific article published on 11 September 2017

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials.

scientific article published on 6 May 2014

Phase I/II RAF kinase inhibitors in cancer therapy ⬇️

scientific article published on 06 May 2013

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies ⬇️

scientific article published on February 7, 2012

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

scientific article published on 11 June 2019

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

scientific article

Renal Cell Cancer: What Can We Learn from Pre-Operative Studies? ⬇️

scientific article published on December 8, 2011

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

scientific article

Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis ⬇️

scientific article published on December 21, 2012

Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance ⬇️

scientific article published on 08 January 2013

Sunitinib for Metastatic Renal Cell Carcinoma ⬇️

scientific article published on September 1, 2010

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

scientific article published on 13 March 2020

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

scientific article published on 17 December 2015

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

scientific article

Systemic thermotherapy: Description of a method and physiologic tolerance in clinical subjects ⬇️

scientific article published on 01 December 1977

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm ⬇️

scientific article published on March 1, 2013

Treatment of brain metastases in patients with melanoma ⬇️

scientific article published on March 27, 2012

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

scientific article

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma ⬇️

scientific article published on August 8, 2012

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

article published in 2015

List of works by James Larkin

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review ⬇️

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Adjuvant nodal irradiation in melanoma

Advances in immunotherapy for melanoma

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies ⬇️

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

Corrigendum re “Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma” [Eur Urol 2017;72:747–54]

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

Current and future systemic treatments for renal cell carcinoma ⬇️

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? ⬇️

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib

Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma

Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III.

Endobronchial metastases from renal cell carcinoma: A late manifestation of the disease with an increasing incidence ⬇️

Expanded access programmes: patient interests versus clinical trial integrity

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma ⬇️

Genome-wide association study identifies multiple risk loci for renal cell carcinoma ⬇️

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?

Ipilimumab activity in advanced uveal melanoma ⬇️

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Metastatic Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Responding to Sunitinib ⬇️

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

New targeted therapies for renal cell carcinoma ⬇️

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Non–Clear Cell Renal Cell Carcinoma: How New Biological Insight May Lead to New Therapeutic Modalities ⬇️

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials.

Phase I/II RAF kinase inhibitors in cancer therapy ⬇️

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies ⬇️

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Renal Cell Cancer: What Can We Learn from Pre-Operative Studies? ⬇️

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis ⬇️

Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance ⬇️

Sunitinib for Metastatic Renal Cell Carcinoma ⬇️

Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

Systemic thermotherapy: Description of a method and physiologic tolerance in clinical subjects ⬇️

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm ⬇️

Treatment of brain metastases in patients with melanoma ⬇️

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma ⬇️

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)